Syngene International plans to add bioconjugation suite for end-to-end Antibody-Drug conjugates development
- byDoctor News Daily Team
- 25 October, 2025
- 0 Comments
- 0 Mins
Mumbai:Syngene International, a global contract research, development and manufacturing organization (CRDMO), is adding a GMP bioconjugation suite at its commercial biologics facility [Unit 3] in Bengaluru. With this new capability, Syngene will offer fully integrated, end-to-end services for antibody-drug conjugates (ADCs) – from discovery through to GMP manufacturing. The OEB-5 rated suite will accelerate ADC development timelines by enabling both Monoclonal Antibodies (mAb) production and GMP bioconjugation at a single site, complementing Syngene’s existing commercial capabilities in payload and linker manufacturing. Expected to be operational within this financial year, the conjugation facility will also support a range of advanced conjugates and related modalities. These services are further strengthened by collocated analytical and bioanalytical capabilities, ensuring seamless integration across the development lifecycle. “The discovery and development of ADCs is complex, often involving multiple vendors and geographically dispersed sites, which adds substantial supply chain complexity and potential delays,” said Alex Del Priore, Head - LM CDMO, Syngene International. “By integrating bioconjugation capabilities with our commercial-scale biologics, payload, and linker production units in Bengaluru, we can significantly compress development timelines and offer a unique, end-to-end pathway from early discovery through to GMP manufacturing.” he added. Syngene is scaling its capabilities to support clinical programs and plans to develop commercial-scale capabilities in the future. Additionally, the laboratories will offer process development, analytical characterization, and scale-up for both early- and late-stage programs. This addition will further enhance Syngene’s ability to serve biotech and biopharma clients seeking agile, science-driven partners for their ADC programs. Syngene will be present at CPHI Frankfurt, Ground Level, Hall Number 6, Booth Number C66. Read also:Syngene International names Chethan Yogesh as Company Secretary, Compliance Officer
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
Tags:
Recent News
Common cholesterol-lowering drugs may reduce risk...
- 27 October, 2025
Colchicine Fails to Improve Outcomes in Long COVID...
- 27 October, 2025
Study uncovers link between brain activity, energy...
- 27 October, 2025
Early-Life Sugar Restriction Linked to Lower Adult...
- 27 October, 2025
Daily Newsletter
Get all the top stories from Blogs to keep track.
0 Comments
Post a comment
No comments yet. Be the first to comment!